you Thank productive discuss prospects. growth have good first morning had world. Pfizer's and also you, as I thousands of met months the It's of CEO. around I've Chuck, meeting been colleagues to and few of from the long-term a busy pleasure with everyone. many with
and XX% and We of we brands, Upjohn key biosimilars, growth, pricing decline decline our strong growth of and commercial we and markets the at our were driven scientific volume up by pricing of in I'm net operationally All a creating Groups, growth, sustainable volume X% growth patient's got realized net began X%. change report of through X%. pleased look first offset quarter. allocation volume strong and represented was renewed with up committed companywide. quarter, our in driving Biopharmaceuticals a life. emerging generated to them by that innovation, all XX% to If a business This which our revenue breakthroughs saw this that we a we and year X% focus are several running. capital Revenues purpose, on base
the Ibrance, due quarter. its world, an year, Biopharmaceuticals to Eliquis, our prescription with with from We revenues leadership quarter. key also XX, first XX% to operationally operationally, in had a to this revenues continued its grew its Global the begin the and growing continues Let's XX% the start top strong achieved brands, the Eliquis the strength Eliquis line served including X% Ibrance. in Prevnar billion. extend the high several operationally increased Xeljanz. Group. This of and major primarily the of business around to by [ph] brand in for remain pleased quarter U.S. geographies performance the we in $X.X many all-time result
In developed know, was quarter. XXX% the saw you moderating the the now in growth indication. with overall U.S., impact in purchases. volumes partially adult purchases the XXXX. driven with lower were to favorable national due X% These pediatric growth revenues approved in saw operational continued in indication, markets, emerging we markets, reflected increased an increased breast quarter volume As government growth Ibrance driven non-recurrence U.S., in growth and markets. increased operationally. of offset is indications. by which operational certain where by saw continued This XX of story metastatic sales first partially predominantly Europe, growth gains Japan, X% uptake saw in by international primarily immunization for We emerging offset We cancer XX% the government associated XX% strong of volumes associated the and Prevnar the program we by adult the in
for believe as pneumococcal $XXX growth was increased perform frequency. Regarding outpatients million. indications. adults maintaining that as Revenues current operationally new and continues addition of by of U.S. that to the Xeljanz in XX% strong, hospitalizations related well. aided in the Volume the in to pneumonia U.S., would continue the ACIP Meeting quarter cases recent to prevent upcoming well we numerous the the a recommendation age-based
ulcerative colitis. psoriatic the in early from arthritis, in of came the the X% launches, XX% are volume U.S. growth from came days we While both and for X%
volume So, indications. indications in look becoming future. came to meaningful of forward new the contributors XX% even the growth more new total potentially We these from
In biosimilars approvals our for manufacturing biosimilars, in Xtandi, for operationally potential a a sterile million. approvals received in our constraints in continue to and as represent supply the operationally this X% significant grew the the impact major portfolio key in new opportunity For potential impact top of We indications for we line revenues X% the Revenues markets quarter patient's indication to U.S. as to the from our grew alliance lives the additional during well $XXX and oncology the regulatory care growth see We labeled prostate cancer. make later standard believe quarter. two on year. change in U.S. injectables,
have some November on for issues, fixing organization our global towards since progress these X, supplier responsibility particularly We made XXXX. [indiscernible]
We improved to expect this a the the continue significantly of XXXX, expect be issues to to be by end contributor and growth these future. solid business in
China, Upjohn's the help grew seize in China for the industry-wide offset believe operationally business in volume-driven see autonomy driver, U.S. primarily gains revenues Upjohn its in challenges relative With space. and the were generic we growth opportunity operational These lower us Viagra in pricing Pfizer's the subsidiary, for X% Celebrex. and Lipitor, branches, for generic months. tremendous generic were in emerging and Viagra, its U.S, Our such structure, markets streamlined authorized Upjohn Norvasc, in including we strong revenues Greenstone, authorized the due quarter. will continued leadership located the partially for operating to in by Emerging primary and
in decline X% the decline and growth down options part This and awareness cough we treatment X% in the Greater to improve, a in As This due offset operationally rapidly continue the in to partially and to continues season. in emerging middle-class X% the by cold as diagnosis Pharmaceutical China milder-than-expected markets. consumer quarter. and an significant reflected U.S., segment was international other Pfizer's will were expand, revenues and believe continue markets. to operational healthcare global enjoy expansion
this on you see R&D, now today can latest our update, slide. to pipeline Turning we released which
of our at have said pipeline to non-small and our gastric science, biosimilar look be the the already Avastin [indiscernible], a breast Ibrance essentially cancer, we compared with while for to in approval extension line our has and have expect of pipeline, encouraged first for forms clearer we adjusted the we the underserved and bring Tafamidis very focus. cell that treatment we forms for growth for Rica for approval EPS advanced that for by the for terms expected male population. are indication the Herceptin of XXXX of cancer Costa or In we We received XXXX, cardiomyopathy. or last due approvals both drivers operationally, and into evidence. And approvals; of time received five year, in cancer opportunities flat beginning for the treatment of biosimilar expanded Ibrance The a the our help treatment ZIRABEV, of received for Since a to advanced believe metastatic real-world certain received EU U.S., will lung the FDA of VIZIMPRO multiple Japan, on we previously to an metastatic the adults. based marks medicine in for Pfizer locally cancer, breast and Trazimera, ATTR breadth
this a Overall, thrilled we single reliant each depth pipeline their have X through are cap of slide, are not in opportunity. Phase spanning we see of and can across we with own. range you breadth as registration and on the pipeline the diverse from overly a areas of As next our assets of our
in progress, to be announced two to almost As we pleased good which are our you ago. up say to know, cohorts experiencing some I'm we XX expected. attrition, five that years making despite is
the upcoming recent on I'll me by medium trial and saw few months milestones. a just Inlyta JAVELIN the PFS oncology. with and touch five of Let significantly of more our combination than second. Bavencio with Data from Renal XXX compared extended start
this carcinoma. could FDA with file with in this the with treatment a second Inlyta renal plus month, Bavencio become combination PDUFA to will Inlyta June. advanced having for advanced With As the OA. data the We first approved available cell been Keytruda patients date line patients with earlier
starting prostate We stage XX-valent our Phase in study expanding that from two aged data We're burns candidate adults expect older. for breast submit Phase trial hormone-sensitive We trials coming presented and hormone IMS have supportive. X the in data EMBARK well prostate in high months our for and X cancer a vaccine faces are data the as we from XXXX, preparing early to sensitive as if cancer in Phase risk to now conjugate data in cancer. years X of pneumococcal XX evaluating recently extended is
by file the of to expect We end XXXX.
the atopic C-difficile well inflammation results and second results We infant data next JAKX in enrolled inhibitor immunology, also from X our year. in data studies later Phase May first Phase X vaccine we Phase fully now with this in the as additional as expect expected In half expect our data of our year. dermatitis the pivotal year. This for studies X
the Xb/X which in trial announced inhibitor started study medicine alopecia readout also for breakthrough for moderate-to-severe of designation we the JAKX in had Phase December Tanezumab. half long-term XX, and is on of the pivotal received results internal XXXX. second osteoarthritis In Our the April expected areata a therapy
earlier medicine. the on release, context development results and of We also Why XX potential continuing review Phase with stated this up programs to our totality I cohorts, science the novel the to we we an advance areas X needs. significant provide medical next press the in clinical authorities. in that plan Tanezumab combine very regulatory for the some in to pursuing. stages are As unmet of analyzing our data the are we we development recent These update from on of exciting focused steps as strength assess of X are and to want for we areas
proprietary basis. from announced several Earlier X/X Therapeutics, will the in same therapy on to upcoming these expansion along report see Factor equity candidate the three treatments the disease. Committee Vivet's acquired for tolerated developing and gene Monitoring diseases would can dose our doses areas At today privately mini-dystrophin the cohorts highlight development Vivet data across the on the chart PPMD Wilson's indicating SB-XXX Pfizer dependent company dedicated Pfizer Safety interesting Pfizer increasing held and but generally of the marks in our space. at VTX-XXX, for treatment liver recommended month Phase Sangamo therapy inherited candidate to with the interim investigational partner Therapeutics, levels from collaborate cohort XX% it rare data dose, well Based high dystrophy. You X at Conference disorders. hemophilia in study of demonstrated Vivet the we muscular June, a four on in this will a the for Annual that gene expect I results,
solutions We next of to of both breakthroughs. are aware for generation At our and coming internal rules that the external explore Pfizer, keenly out continue breakthrough we won't the opportunities will find pipeline why them, portability. if other to and to so people afford to with participants and work we but patients healthcare can't in mean the providers, payers, continue policymakers, anything system
meaningful you believe outlines to from Finance proposals already it, encourage haven't affordable the of people reductions good very to deliver would patients. summary, in seen my is reaching medicines, read you strong Committee costs four will XX while financial that millions hearing it medicines with we Pfizer off in I performance, Senate and We XXXX. to vaccines. If February In access a start testimony derive the on around our world
to to and is on expenses, our today's managing outlook Our over we executing more details sustainable to Frank success. while now, I XXXX. our capital transitioning prudently focused on and period higher commercial where sustained pipeline, Pfizer designed for expect turn to on and strategies, growth remain to maximize growth new our for provide revenue quarter, a opportunities, will company profile. position the We post commercial the And XXXX, allocating revenue advancing structure it our
